Biologicals (Pharmacology)

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Biologicals (Pharmacology).php on line 2
Biologicals (Pharmacology)

LE WE PMID CA

Biologicals (Pharmacology)

4734

Biologicals (Pharmakologie)

Biologicals (Pharmacology)

Radiopharmacology

TNF alpha

2009 1	Infectious complications associated with monoclonal antibodies and related small molecules. [19366915] Clin Microbiol Rev 22(2): 274-90, Table of Contents (2009)
2009 2	Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. [19861045] Emerg Infect Dis 15(10): 1556-61 (2009)
2009 3	Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe. [19523302] Emerg Infect Dis 15(6): 956-9 (2009)
2006 4	Adverse side-effects to biological agents. [16867042] Allergy 61(8): 912-20 (2006)
2006 5	A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents. [17105851] Ann Rheum Dis 65(12): 1541-4 (2006)
2008 6	Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. [17944997] Aliment Pharmacol Ther 27(1): 19-30 (2008)
2003 7	Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. [12492735] Aliment Pharmacol Ther 17(1): 75-84 (2003)
2009 8	Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. [19210297] Aliment Pharmacol Ther 29(9): 921-7 (2009)
2008 9	The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. [18485127] Aliment Pharmacol Ther 28(2): 221-7 (2008)
2009 10	Skin toxicities associated with epidermal growth factor receptor inhibitors. [19452131] Target Oncol 4(2): 107-19 (2009)
2009 11	Renal toxicity of targeted therapies. [19421832] Target Oncol 4(2): 121-33 (2009)
2009 12	Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. [19381453] Target Oncol 4(2): 99-105 (2009)
2009 13	Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. [19373440] Target Oncol 4(2): 67-76 (2009)
2008 14	Hematopoietic growth factors: ESMO recommendations for the applications. [18456747] Ann Oncol 19 Suppl 2(-): ii116-8 (2008)
2007 15	The clinical use of antibodies in haematological malignancies. [17631596] Ann Oncol 18 Suppl 9(-): ix51-7 (2007)
2005 16	Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. [16012181] Ann Oncol 16(9): 1425-33 (2005)
2007 17	Mechanisms of adverse effects of anti-VEGF therapy for cancer. [17519900] Br J Cancer 96(12): 1788-95 (2007)
2007 18	Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. [17429839] Cancer 109(11): 2182-9 (2007)
2003 19	Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs? [12684387] Clin Cancer Res 9(4): 1231-2 (2003)
2008 20	Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. [18779536] Oncologist 13(9): 1001-11 (2008)
2008 21	Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. [18586928] Oncologist 13(6): 725-32 (2008)
2007 22	Review: side effects of approved molecular targeted therapies in solid cancers. [18165622] Oncologist 12(12): 1443-55 (2007)
2007 23	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. [17934088] Ann Rheum Dis 66 Suppl 3(-): iii2-22 (2007)
2005 24	Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. [16239380] Ann Rheum Dis 64 Suppl 4(-): iv2-14 (2005)
2011 25	Promising new treatments for rheumatoid arthritis - the kinase inhibitors. [22035435] Bull NYU Hosp Jt Dis 69(3): 233-7 (2011)
2009 26	Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. [19880688] Mayo Clin Proc 84(11): 979-84 (2009)
2008 27	Development of sarcoidosis during etanercept therapy. [18520114] Intern Med 47(11): 1021-5 (2008)
2011 28	Cutaneous side-effects of EGFR inhibitors and their management. [21293833] Skin Therapy Lett 16(1): 1-3 (2011)
2007 29	Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. [17762902] Skin Therapy Lett 12(6): 1-5 (2007)
2010 30	How tumour necrosis factor blockers interfere with tuberculosis immunity. [20491796] Clin Exp Immunol 161(1): 1-9 (2010)
2011 31	Molecular target therapy in hematological malignancy: front-runners and prototypes of small molecule and antibody therapy. [21113055] Jpn J Clin Oncol 41(2): 157-64 (2011)
2009 32	Long-term efficacy of biologics in dermatology. [19222514] Dermatol Ther 22(1): 22-33 (2009)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Biologicals (Pharmacology).php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Biologicals (Pharmacology).php on line 92